Epizyme's tazemetostat shows positive effect in mid-stage lymphoma study [Seeking Alpha]
Epizyme, Inc. (EPZM)
Last epizyme, inc. earnings: 2/24 06:30 am
Check Earnings Report
US:NASDAQ Investor Relations:
epizyme.com
Company Research
Source: Seeking Alpha
Epizyme's tazemetostat shows positive effect in mid-stage lymphoma studyPreliminary results from a Phase 2 clinical trial evaluating Epizyme's (NASDAQ:EPZM) lead drug tazemetostat in heavily pretreated follicular lymphoma (FL) patients showed a treatment effect. The data are being presented at EULAR in Amsterdam.In 82 evaluable patients, the objective response rate (ORR) was 71% (n=58/82) including an 11% (n=9/82) complete response rate. The disease control rate (DCR) (responders + stable cancer) was 100% (n=82/82).Median progression-free survival (PFS) was 49 weeks and median duration of response was 32 weeks, both continue to mature.In the cohort of wild-type FL patients, the ORR was 33% (n=18/54), including a complete response rate of 6% (n=3/54). The DCR was 65% (n=35/54).Tazemetostat was generally well-tolerated. There was a 6% discontinuation rate. 17% of adverse events (AEs) were Grade 3 (serious) or higher, the most frequent being thrombocytopenia, anemia, asthenia (weakness/l
Show less
Read more
Impact Snapshot
Event Time:
EPZM
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
EPZM alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
EPZM alerts
High impacting Epizyme, Inc. news events
Weekly update
A roundup of the hottest topics